CAB-CD19 x CD3 T-cell Engager

About BioAtla

BioAtla's mission is to revolutionize cancer therapy by developing smarter, more targeted biologics with an improved therapeutic index. Its core achievement is the patented Conditionally Active Biologics (CAB) platform, which creates therapeutics activated specifically in the tumor microenvironment. The company's strategy leverages this platform to build a pipeline of CAB-based antibody-drug conjugates (ADCs) and T-cell engagers, targeting both novel and validated oncology antigens with potentially superior safety profiles. Despite promising technology, the company faces significant clinical and financial challenges as it advances its lead candidates through mid-stage trials.

Therapeutic Areas

Other B-cell Malignancies Drugs